Get started

PFIZER

PFE | Good Starter Position Entry | LONGPfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
NYSE:PFELong
by DivergenceSeeker
3
#LUPIN #LAURUSLABS #ZYDUSLIFE #APOLLOHOSP #FORTIS #AARTIDRUGS #I#LUPIN NSE: LUPIN CMP: 756 TP: 910 SL: 700 TF: <6m RR > 3 times Return > 20% THYROCARE CNXPHARMA LUPIN NSE:CIPLA SUNPHARMA SPARC DIVISLAB DRREDDY AUROPHARMA BALPHARMA GLENMARK SANOFI PFIZER BPLPHARMA MARKSANS BIOCON GRANULES IPCALAB LAURUSLABS NATCOPHARM GLAND ALKEM ZYDUSLIFE APOLLOHOSP FORTIS AARTIDRUGS Factors: BULLISH WEDGE BREAKOUT Trend Following Rising Volume with rising Prices. Flag pattern breakout. Pennant Pattern Breakout with Bullish Candle. Retest Successful. Higher Highs & Higher Lows. Broken above RESISTANCE levels Trading at SUPPORT levels Earnings are strong. Bullish Wedge Breakout Risk Return Ratio is healthy. And Rising from Double Bottom Pattern to Flag Pattern forming. If you like my work KINDLY LIKE SHARE & FOLLOW this page for free Stock Recommendations. With 💚 from Rachit Sethia
NSE:LUPINLong
by Rachit_Sethia
#AUROPHARMA #CIPLA #DIVISLAB #DRREDDY #LUPIN #GLENMARK #PFIZER #AUROPHARMA NSE: AUROPHARMA CMP: 437 TP: 535 SL: 400 TF: <6m RR > 3.5 times Return > 22% THYROCARE CNXPHARMA LUPIN NSE:CIPLA SUNPHARMA SPARC DIVISLAB DRREDDY AUROPHARMA BALPHARMA GLENMARK SANOFI PFIZER Factors: BULLISH WEDGE BREAKOUT Trend Following Rising Volume with rising Prices. Flag pattern breakout. Pennant Pattern Breakout with Bullish Candle. Retest Successful. Higher Highs & Higher Lows. Broken above RESISTANCE levels Trading at SUPPORT levels Earnings are strong. Bullish Wedge Breakout Risk Return Ratio is healthy. And Rising from Double Bottom Pattern to Flag Pattern forming. If you like my work KINDLY LIKE SHARE & FOLLOW this page for free Stock Recommendations. With 💚 from Rachit Sethia
NSE:AUROPHARMALong
by Rachit_Sethia
2
#GLENMARK #SANOFI #PFIZER #BPLPHARMA #MARKSANS #BIOCON #GRANULES#GLENMARK NSE: GLENMARK CMP: 440 TP: 515 SL: 400 TF: <6m RR > 2 times Return > 17% THYROCARE CNXPHARMA LUPIN NSE:CIPLA SUNPHARMA SPARC DIVISLAB DRREDDY AUROPHARMA BALPHARMA GLENMARK SANOFI PFIZER BPLPHARMA MARKSANS BIOCON GRANULES IPCALAB LAURUSLABS NATCOPHARM GLAND ALKEM ZYDUSLIFE Factors: BULLISH WEDGE BREAKOUT Trend Following Rising Volume with rising Prices. Flag pattern breakout. Pennant Pattern Breakout with Bullish Candle. Retest Successful. Higher Highs & Higher Lows. Broken above RESISTANCE levels Trading at SUPPORT levels Earnings are strong. Bullish Wedge Breakout Risk Return Ratio is healthy. And Rising from Double Bottom Pattern to Flag Pattern forming. If you like my work KINDLY LIKE SHARE & FOLLOW this page for free Stock Recommendations. With 💚 from Rachit Sethia
NSE:GLENMARKLong
by Rachit_Sethia
#CIPLA #BALPHARMA #GLENMARK #SANOFI #PFIZER #AUROPHARMA #NIFTY50#CIPLA NSE: CIPLA CMP: 1128 TP: 1250 SL: 1080 TF: <6m RR > 2.5 times Return > 11% THYROCARE CNXPHARMA LUPIN NSE: CIPLA SUNPHARMA SPARC DIVISLAB DRREDDY AUROPHARMA BALPHARMA GLENMARK SANOFI PFIZER Factors: BULLISH WEDGE BREAKOUT Trend Following Rising Volume with rising Prices. Flag pattern breakout. Pennant Pattern Breakout with Bullish Candle. Retest Successful. Higher Highs & Higher Lows. Broken above RESISTANCE levels Trading at SUPPORT levels Earnings are strong. Bullish Wedge Breakout Risk Return Ratio is healthy. And Rising from Double Bottom Pattern to Flag Pattern forming. If you like my work KINDLY LIKE SHARE & FOLLOW this page for free Stock Recommendations. With 💚 from Rachit Sethia
NSE:CIPLALong
by Rachit_Sethia
7
Pfizer in a bull flag.Pfizer - 30d expiry - We look to Buy a break of 48.31 (stop at 46.56) Short term bias has turned positive. Posted a bullish Flag formation. A break of 48.26 is needed to confirm the outlook. A break of the recent high at 48.26 should result in a further move higher. Short term momentum is bullish. This stock has seen good sales growth. The bias is to break to the upside. Our profit targets will be 52.69 and 53.69 Resistance: 48.00 / 49.70 / 52.00 Support: 46.70 / 46.00 / 44.70 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis , like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis , as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NYSE:PFELong
by Saxo
1
PFIZER Broke above its 2022 Bear Channel!Pfizer (PFE) broke and closed today above the Channel Down that has been dominating the 2022 Bear Market since the January 11 High. At the same time the 1D RSI has been ranging and while the 1D MA200 (orange trend-line) held successfully last time, we do expect one last test or for an even more comfortable long-term buy, the 1D MA50 (blue trend-line). As you may notice, the Fibonacci retracement levels since the All Time High, formed solid Resistance and Support levels during the downtrend, so after the next pull-back our target will by the 0.786 Fib at 57.35. ------------------------------------------------------------------------------- ** Please LIKE 👍, SUBSCRIBE ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support me, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- You may also TELL ME 🙋‍♀️🙋‍♂️ in the comments section which symbol you want me to analyze next and on which time-frame. The one with the most posts will be published tomorrow! 👏🎁 ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:PFE
by TradingShot
2
Accumulating PFE from $46.00 - $47.50 This is one of the stocks I hold indefinitely for dividends. we're at the bottom of our current channel and a double bottom is forming in a major area of support. In my previous post I stated my accumulation sections are in the lower end of the channel, so this is prime real estate to enter. Momentum downwards has come to a halt and I believe we will retest the center channel line from this point. I am diversifying a portion of profits I made from the last 2 trade set ups I've posted into PFE. A fundamentally sound entity in our current market economy. I'm sure you could assume why.
NYSE:PFELong
by WatsonsView
PFE: Triangle break!Pfizer Short Term - We look to Sell at 50.48 (stop at 52.47) Our outlook is bearish. Broken out of the triangle formation to the downside. This is negative for sentiment and the downtrend has potential to return. Further downside is expected although we prefer to sell into rallies close to the 51.00 level. Our profit targets will be 45.49 and 42.00 Resistance: 50.00 / 54.00 / 62.00 Support: 45.00 / 40.00 / 34.00 Please be advised that the information presented on TradingView is provided to Vantage (‘Vantage Global Limited’, ‘we’) by a third-party provider (‘Signal Centre’). Please be reminded that you are solely responsible for the trading decisions on your account. There is a very high degree of risk involved in trading. Any information and/or content is intended entirely for research, educational and informational purposes only and does not constitute investment or consultation advice or investment strategy. The information is not tailored to the investment needs of any specific person and therefore does not involve a consideration of any of the investment objectives, financial situation or needs of any viewer that may receive it. Kindly also note that past performance is not a reliable indicator of future results. Actual results may differ materially from those anticipated in forward-looking or past performance statements. We assume no liability as to the accuracy or completeness of any of the information and/or content provided herein and the Company cannot be held responsible for any omission, mistake nor for any loss or damage including without limitation to any loss of profit which may arise from reliance on any information supplied by Signal Centre.
NYSE:PFEShort
by VantageMarkets
Pfizer | Fundamental Analysis | Must ReadSo far this year has not been kind to stock markets. And while many drug makers have avoided a selloff, Pfizer is not one of them. The pharmaceutical giant has performed more or less on par with the broader market to date. Fortunately, Pfizer's latest quarterly report showed some very encouraging signs. However, there are also reasons to be concerned about the future of this medical company. Let's look at one earnings-related reason why Pfizer might be a buy and one reason why it might not be. Pfizer has made a fortune over the past couple of years through its work on coronaviruses. The company continues to benefit greatly from these efforts. In Q2, the company's revenues rose 53% year over year to $27.7 billion. According to company executives, Pfizer recorded the largest quarterly sales in its history during the period, and that was primarily due to its COVID-19 product line. Sales of the coronavirus vaccine totaled $8.8 billion, up 20% from last year. Sales of the coronavirus drug Paxlovid were $8.1 billion (no year-over-year comparison here, since the drug received approval in December). These two drugs alone accounted for more than half of Pfizer's total revenue. While Pfizer's line of drugs against coronaviruses is currently unparalleled, the rest of the company's portfolio is not as impressive. The non-coronavirus drug maker's revenues grew a paltry 1% year-over-year in Q2. Pfizer's line of drugs faces a number of challenges, including adverse events related to its immunologic drug Xeljanz. Xeljanz belongs to a class of drugs known as JAK inhibitors. Last year, Pfizer published data from a post-marketing study that showed Xeljanz was associated with higher rates of cardiovascular events and cancer than TNF inhibitors, a drug category that includes AbbVie's Humira. The results of this study, combined with a regulatory decision to add a warning about these risks to the label of Xeljanz (and other JAK inhibitors), are holding back sales of the drug. In Q2, sales of Xeljanz declined 24% year over year to $430 million. Revenues for the immunosuppressant Enbrel also fell 10% year over year to $257 million, probably because of tougher competition, which also affected its sales in Q1. Pfizer has some good non-coronavirus numbers, including its drug Eliquis. In Q2, sales of that anticoagulant rose 23% year over year to $1.7 billion. But overall, the company has barely been able to increase sales outside of its line of coronavirus drugs. This could be a problem if sales of COVID-19 products fall sharply after this year. In my opinion, the market is still underestimating Pfizer. First, the company will continue to make profits from Paclovid and Comirnati. COVID-19 will not (unfortunately) suddenly disappear out of thin air after this year. Even if the demand for drugs to prevent or treat the disease declines, Paxlovid and Komirnati can continue to make significant contributions to Pfizer's top-line revenue for a long time to come. Second, while the rest of the drug line is unimpressive, pharmaceutical companies sometimes face this problem because of growing competition, patent breaks, or other factors. But drug makers generally don't have the advantage of growing sales at the rate that Pfizer does when they face such obstacles. What matters is whether the company in question can meet these challenges. Having a solid portfolio and plenty of money to devote to research and development helps - and Pfizer has both. Thanks to the company's success in the coronavirus market, its cash balance has skyrocketed. Pfizer has been active in acquisitions and plans to continue on that path. This should help bolster its already solid line of drugs, which has more than 90 clinical trials. Pfizer expects up to 15 new approvals over the next 18 months. Some of the current programs could go wrong. But the company has all the tools it needs to launch several new potential blockbuster drugs in the next five years. That's why investors should siphon off the company's stock before it rises in price.
NYSE:PFELong
by FOREXN1
10
Pfizer: Playing the range againPfizer Short Term We look to Sell at 54.06 (stop at 56.08) Bespoke resistance is located at 54.50. A move higher faces tough resistance and we remain cautious on upside potential. Selling spikes offers good risk/reward. Further downside is expected although we prefer to sell into rallies close to the 54.60 level. We are trading at overbought extremes. Our profit targets will be 46.80 and 44.60 Resistance: 54.50 / 56.32 / 61.71 Support: 50.00 / 46.50 / 40.94 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NYSE:PFEShort
by Saxo
Pfizer at resistancePfizer Short Term - We look to Sell at 54.62 (stop at 56.31) Bespoke resistance is located at 54.70. A move higher faces tough resistance and we remain cautious on upside potential. Selling spikes offers good risk/reward. Further downside is expected although we prefer to sell into rallies close to the 54.60 level. Trading has been mixed and volatile. Our profit targets will be 49.84 and 46.85 Resistance: 54.70 / 56.32 / 61.71 Support: 50.00 / 47.50 / 40.94 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NYSE:PFEShort
by Saxo